Analysts weigh Novo Nordisk against Regeneron for 2026 investors
A comparison piece pits the obesity drugmaker against Regeneron as competing healthcare stock picks for the year.
TR
By Tom Reyes · Markets Editor
Sep 15 09:09 ETSource: finance.yahoo.com
The wire
- 01Commentary compares Novo Nordisk and Regeneron as healthcare investment options in 2026.
- 02Reflects continued investor scrutiny of Novo's position amid GLP-1 competition.
- 03No new company disclosures or financial results accompany the comparison.
From the source
Read at news.google.comNovo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026?